Igawa S, et al. - The efficacy of platinum-based chemotherapy as second-line treatment for elderly patients and patients with small-cell lung cancer (SCLC) and a poor performance status (PS) previously treated with amrubicin monotherapy was determined. It was shown that platinum-based chemotherapy affords a potentially valid option as second-line chemotherapy for treating elderly patients or patients with extensive-stage SCLC and poor PS who progressed after first-line treatment with amrubicin monotherapy.